Compare INCY & WSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCY | WSO |
|---|---|---|
| Founded | 1991 | 1945 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 14.1B |
| IPO Year | 1993 | N/A |
| Metric | INCY | WSO |
|---|---|---|
| Price | $106.24 | $371.53 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 8 |
| Target Price | $96.79 | ★ $426.67 |
| AVG Volume (30 Days) | ★ 2.2M | 351.1K |
| Earning Date | 02-09-2026 | 02-17-2026 |
| Dividend Yield | N/A | ★ 3.20% |
| EPS Growth | ★ 3878.02 | N/A |
| EPS | 5.90 | ★ 12.87 |
| Revenue | $4,813,105,000.00 | ★ $7,414,495,000.00 |
| Revenue This Year | $19.59 | N/A |
| Revenue Next Year | $10.80 | $3.74 |
| P/E Ratio | ★ $17.52 | $29.09 |
| Revenue Growth | ★ 18.09 | N/A |
| 52 Week Low | $53.56 | $323.05 |
| 52 Week High | $112.29 | $535.40 |
| Indicator | INCY | WSO |
|---|---|---|
| Relative Strength Index (RSI) | 57.76 | 61.86 |
| Support Level | $102.68 | $346.48 |
| Resistance Level | $112.29 | $381.70 |
| Average True Range (ATR) | 3.15 | 10.36 |
| MACD | 0.44 | 3.24 |
| Stochastic Oscillator | 58.73 | 77.34 |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.